Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)
Published: Feb. 3, 2025
Language: Английский
Gastroenterology, Journal Year: 2024, Volume and Issue: 167(4), P. 689 - 703
Published: April 29, 2024
Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC preventable with about 70% attributable to modifiable risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), Food and Drug Administration-approved medications for treating type 2 diabetes mellitus (T2DM), have pleiotropic effects on counteracting factors HCC. Here we evaluate the association GLP-1RAs incident in real-world population.
Language: Английский
Citations
37
Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350
Published: April 24, 2024
BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.
Language: Английский
Citations
25
Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108
Published: March 12, 2024
This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.
Language: Английский
Citations
19
Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)
Published: Jan. 11, 2025
This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.
Language: Английский
Citations
7
Cells, Journal Year: 2025, Volume and Issue: 14(3), P. 221 - 221
Published: Feb. 4, 2025
Cigarette smoke (CS), an intricate blend comprising over 4000 compounds, induces abnormal cellular reactions that harm multiple tissues. Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic (CLD), encompassing non-alcoholic (NAFL), steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Recently, the term NAFLD has been changed to metabolic dysfunction-associated steatotic (MASLD), NASH renamed (MASH). A multitude of experiments have confirmed association between CS incidence progression MASLD. However, specific signaling pathways involved need be updated with new scientific discoveries. exposure can disrupt lipid metabolism, induce inflammation apoptosis, stimulate fibrosis through promote Currently, there no officially approved efficacious pharmaceutical intervention in clinical practice. Therefore, lifestyle modifications emerged as primary therapeutic approach for managing Smoking cessation application series natural ingredients shown ameliorate pathological changes induced by CS, potentially serving effective decelerating MASLD development. This article aims elucidate which smoking promotes MASLD, while summarizing reversal factors identified recent studies, thereby offering novel insights future research on treatment
Language: Английский
Citations
2
Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(11), P. 9084 - 9102
Published: Nov. 14, 2023
The central mechanism involved in the pathogenesis of MAFLD is insulin resistance with hyperinsulinemia, which stimulates triglyceride synthesis and accumulation liver. On other side, free fatty acid hepatocytes promotes via oxidative stress, endoplasmic reticulum lipotoxicity, increased secretion hepatokines. Cytokines adipokines cause resistance, thus promoting lipolysis adipose tissue ectopic fat deposition muscles Free acids along cytokines contribute to liver activation numerous signaling pathways. hepatokines, hormone-like proteins, primarily by disturbed impairs pathways, causing metabolic dysregulation ER stress unfolded protein response play significant roles aggravation through apoptosis, inflammatory response, impairment mediated IRE1/PERK/ATF6 pathways upregulation SREBP 1c. Circadian rhythm derangement biological clock desynchronization are related disorders, NAFLD, suggesting genes as a potential target for new therapeutic strategies. This review aims summarize mechanisms hepatic NAFLD development progression.
Language: Английский
Citations
28
Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15
Published: May 8, 2024
Background The estimated glucose disposal rate (eGDR), an effective indicator of insulin resistance, has been related to acute coronary syndrome, ischemic stroke and heart failure. This study aims explore the relationship between eGDR arterial stiffness, all-cause mortality cardiovascular in patients with non-alcoholic fatty liver disease (NAFLD). Methods Participants NAFLD were chosen from National Health Nutrition Examination Survey (NHANES) 1999 2018. main outcomes are stiffness (represented by pulse wave velocity, ePWV), mortality. Multiple cox regression models, restricted cubic spline, sensitivity analysis subgroup carried out investigate correlation resistance indicators stiffness. Furthermore, receiver operating characteristic curves used compare predictive value triglyceride-glucose (TyG) index homeostasis model assessment (HOMA-IR) for Results In this study, a total 4,861 participants included analysis. After adjusting confounding factors multivariate weighted model, was inversely associated (Q4 vs. Q1, HR =0.65 (0.48-0.89, P=0.01) =0.35 (0.19-0.65, P<0.001). Compared TyG HOMA-IR, shows excellent (0.588 0.550 0.513, P < 0.001) (0.625 0.553 0.537, 0.001). addition, we found significant negative (β=-0.13(-0.14–0.11, P< However, HOMA-IR showed no Conclusions Low (an resistance) levels increased risk United States.
Language: Английский
Citations
14
Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220
Published: July 11, 2024
Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.
Language: Английский
Citations
14
Liver International, Journal Year: 2024, Volume and Issue: 44(10), P. 2538 - 2550
Published: July 1, 2024
We examined the impact of a co-diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.
Language: Английский
Citations
12
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14
Published: Jan. 19, 2024
In light of a global rise in the number patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated (MAFLD) or steatotic (MASLD), has become leading cause hepatocellular carcinoma (HCC), annual occurrence MASLD-driven HCC expected to increase by 45%–130% 2030. Although MASLD serious major public health threat globally, exact molecular mechanisms mediating remain an open problem, necessitating future investigation. Meanwhile, emerging studies are focusing on utility bioactive compounds halt progression HCC. this review, we first briefly review recent progress possible pathogenesis for We then discuss application mitigate through different modulatory encompassing anti-inflammatory, lipid metabolic, gut microbial pathways, providing valuable information treatment prevention Nonetheless, clinical research exploring effectiveness herbal medicines is still warranted.
Language: Английский
Citations
11